JNMT
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nair, N.
Right arrow Articles by Basu, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nair, N.
Right arrow Articles by Basu, S.
Journal of Nuclear Medicine Technology Volume 33, Number 3, 2005 166-171
© 2005 by Society of Nuclear Medicine

Selected Cases Demonstrating the Value of Furosemide-Primed 18F-FDG PET in Identifying Adrenal Involvement

Narendra Nair, MD; and Sandip Basu, MBBS(Hons), DRM, DNB

Radiation Medicine Centre, Bhabha Atomic Research Centre, Bombay, India

The adrenals are often a site of metastatic spread of cancer, and evaluation of the adrenals is important in assessing the extent of disease involvement in several malignancies. PET with 18F-FDG has been found extremely effective in detecting adrenal involvement not identified on CT or not meeting the CT size criteria for malignancy. However, evaluation of the adrenals and of retroperitoneal adenopathy or other pathologic conditions with 18F-FDG PET can be complicated at times by normal accumulation of the tracer in the uppermost renal calyx because of its somewhat posterior orientation, particularly when it is dilated. It is not infrequent for physicians to report doubt about adrenal involvement and to suggest that the PET findings be correlated with CT findings. This problem can often be circumvented clinically by administering intravenous furosemide (dosage adjusted according to body weight) to remove 18F-FDG activity from the renal pelvicalyceal system and by rescanning approximately 15–20 min later using 1–2 bed positions that include the renal area. We present 5 case vignettes, with representative illustrations, providing convincing evidence of the usefulness of this simple, noninvasive interventional procedure in ruling out suspected adrenal involvement that is otherwise difficult to assess, thereby obviating any further confirmation.

Key Words: 18F-FDG PET; furosemide; adrenal metastasis




This article has been cited by other articles:


Home page
JNMHome page
E. M. Kamel, P. Jichlinski, J. O. Prior, J.-Y. Meuwly, J.-F. Delaloye, L. Vaucher, J. Malterre, S. Castaldo, H.-J. Leisinger, and A. B. Delaloye
Forced Diuresis Improves the Diagnostic Accuracy of 18F-FDG PET in Abdominopelvic Malignancies
J. Nucl. Med., November 1, 2006; 47(11): 1803 - 1807.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE JOURNAL OF NUCLEAR MEDICINE JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY
Copyright © 2005 by the Society of Nuclear Medicine Technologist Section.